Roche’s oral SERD fails in Phase III breast cancer trial
Roche’s oral selective oestrogen receptor degrader (SERD) has failed to meet its primary endpoint in a Phase III breast cancer…
News
Analysts tout market potential of Xenon’s epilepsy drug on Phase III win
Vinay Prasad to leave the FDA again
Dyne commences Phase III HARMONIA trial for DM1 therapy
Aisa Pharma reports positive results for AISA-021
Roche and Zealand’s Phase II obesity trial divides analyst opinion
EMA posts draft guidance on running trials during public health emergencies
DiaMedica gains Health Canada approval for Phase II preeclampsia trial
